Factory 99% Polymyxin B Powder CAS 1404-26-8 Antibiotic Polymyxin B

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A588
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Polymyxin B
• CAS: 1404-26-8
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Antibiotic
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Polymyxin B
Appearance	White Powder
CAS NO.	1404-26-8
MF	C56H101N17O13
Storage	Keep in a cool, dry, dark location

 

Polymyxin B is an antibiotic belonging to the polymyxin class of drugs. It is derived from the bacterium Bacillus polymyxa and exhibits potent antibacterial activity against a wide range of Gram-negative bacteria.

 

1. Treatment of Gram-Negative Infections: Polymyxin B is primarily used in the treatment of severe infections caused by Gram-negative bacteria, such as Pseudomonas aeruginosa and Escherichia coli.
2. Topical Applications: It is also available in topical formulations for the treatment of skin and eye infections caused by susceptible bacteria.
3. Combination Therapy: Polymyxin B is often used in combination with other antibiotics, such as beta-lactams, to broaden the spectrum of antibacterial activity and enhance therapeutic efficacy.

1. Bacterial Cell Membrane Disruption: Polymyxin B binds to the lipopolysaccharide component of the bacterial cell membrane, causing disruption and leading to the leakage of cellular contents and eventual cell death.
2. Antibacterial Activity: It exhibits potent bactericidal activity against Gram-negative bacteria by disrupting their cell membranes and inhibiting cell growth and replication.
3. Synergistic Effect with Other Antibiotics: Polymyxin B can enhance the antibacterial activity of other antibiotics when used in combination, making it a valuable tool in the treatment of multidrug-resistant infections.